Sun | Oct 24, 2021

FDA grapples with timing of booster for J&J COVID-19 vaccine

Published:Wednesday | October 13, 2021 | 11:37 AM
In this Wednesday, March 3, 2021, file photo, a pharmacist holds a vial of the Johnson & Johnson COVID-19 vaccine at a hospital in Bay Shore, New York. Janssen Pharmaceuticals is a division of Johnson & Johnson. On Wednesday, October 13, 2021, the Food and Drug Administration said it is wrestling with whether and when recipients of the single-shot Johnson & Johnson COVID-19 vaccine need another dose — at six months or as early as two months. (AP Photo/Mark Lennihan)

WASHINGTON (AP) — The Food and Drug Administration said Wednesday it is wrestling with whether and when recipients of the single-shot Johnson & Johnson COVID-19 vaccine need another dose — at six months or as early as two months.

In an online review, FDA scientists didn't reach a firm conclusion, citing shortcomings with J&J's data, including little information on protection against the extra-contagious delta variant of the coronavirus.

The review comes ahead of meetings Thursday and Friday when an FDA advisory panel will recommend whether to back booster doses of both the J&J and Moderna vaccines.

That's one step in the government's vaccine review process: Next week, the FDA will make a final decision on authorising those boosters and then the Centers for Disease Control and Prevention will debate who actually should get them.

Health authorities say all the vaccines used in the US continue to provide strong protection against severe disease or death from COVID-19.

But amid signs that protection against milder infections may be waning, the government already has cleared booster doses of the Pfizer vaccine for certain people starting at six months after their last shot.

Aiming for uniform recommendations, Moderna likewise asked the FDA to clear its booster dose at six months.

But J&J complicated the decision by proposing a second shot over a range of two to six months.

FDA reviewers wrote that a study of the two-month booster plan suggests “there may be a benefit,” while pointing to only small numbers of people who got another shot at six months instead.

Overall, the J&J vaccine “still affords protection against severe COVID-19 disease and death,” the FDA's reviewers concluded.

But data about its effectiveness “are consistently less” than the protection seen with Pfizer and Moderna shots.

For its part, J&J filed data with the FDA from a real-world study showing its vaccine remains about 80% effective against hospitalisations in the US.

J&J's single-dose vaccine was highly anticipated for its one-and-done formulation.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.